Loading peptide library…
PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.
Explore research-backed breakdowns of each peptide — mechanisms, benefits, typical protocols, and notable studies. Search or filter by category to find what you need.
30 peptides
A stabilized GHRH analog FDA-approved to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Studied for its strong effect on visceral adipose tissue.
A modified fragment of the C-terminus of human growth hormone (residues 176-191) studied for fat-loss effects without the broader growth-promoting actions of full GH.
A long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Among the most effective approved weight-loss therapies.
A dual GIP and GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound), with weight-loss results that often exceed GLP-1-only agents.
A combination pairing the fat-loss GH fragment AOD-9604 with the GHRH analog CJC-1295, studied to layer direct lipolytic activity onto elevated endogenous growth hormone.
5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, studied in animal models for its potential to reduce fat storage and support metabolic health.
Adipotide is an experimental peptidomimetic studied in animals for targeted destruction of the blood supply feeding white fat tissue.
AICAR (Acadesine) is an AMPK-activating compound studied as an exercise-mimetic for endurance and metabolic effects in animals. Note: AICAR is a small-molecule nucleoside (an AMPK activator), not a peptide, but is commonly sold alongside research peptides.
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
HGH Fragment 176-191 is the C-terminal fragment of human growth hormone studied primarily for its fat-reducing effects without the broader growth-promoting actions of full-length GH. It is a popular research compound for lipolysis.
Pancragen is a synthetic short peptide bioregulator (Lys-Glu-Asp-Trp) studied in Russian research for supporting pancreatic function and glucose metabolism. It belongs to the Khavinson family of peptide bioregulators developed to normalize tissue-specific gene expression in aging organs.
Retatrutide is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRs) studied as an exercise mimetic that increases fat oxidation and endurance in animal models. It is a research chemical, not a peptide.
Mazdutide (IBI362) is an investigational dual agonist of the GLP-1 and glucagon receptors based on the oxyntomodulin scaffold. It is being studied for weight loss and glycemic control.
Survodutide (BI 456906) is an investigational dual agonist of the glucagon and GLP-1 receptors developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is administered as a once-weekly subcutaneous injection.
Tyr-hGH 177-191 is a tyrosine-extended analog of the C-terminal lipolytic fragment of human growth hormone. The added tyrosine residue is used mainly to enable labeling and tracing while the fragment retains the fat-mobilizing activity associated with the 176-191 region.
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA region that acts as a regulator of metabolism. It is studied for improving insulin sensitivity, metabolic flexibility, and exercise capacity.
NMN is a direct biosynthetic precursor of NAD+ used to raise cellular NAD+ levels. It is studied for longevity, metabolic health, and mitochondrial function. Note: NMN is a small-molecule NAD+ precursor, not a peptide, but is catalogued with longevity research compounds.
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist in late-stage clinical development for obesity and type 2 diabetes. It is studied for weight loss and glycemic control without injections.
Tesofensine is a triple monoamine reuptake inhibitor originally developed for neurodegenerative disease and later investigated as an anti-obesity drug. It produces appetite suppression and notable weight loss in clinical trials. Note: Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide, but is sold alongside metabolic research compounds.
A small-molecule mitochondrial protonophore (uncoupler) studied as a metabolic compound for fat loss and metabolic health. It is not a peptide but is commonly sold alongside research peptides.
EP-23905 is an obscure investigational research compound studied in early metabolic and appetite-signaling work. Very limited public data exists, and it is sold strictly for laboratory research use.
Ghrelin Acetate is the acetate salt of ghrelin, the endogenous gut-derived hormone that drives hunger and stimulates growth hormone release. It is studied for appetite and GH-axis research.
Liraglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. Its fatty-acid modification gives it a once-daily dosing profile.
A three-part research blend combining the lipolytic HGH Fragment 176-191 with the GHRH analog CJC-1295 (No DAC) and the selective ghrelin-receptor agonist Ipamorelin. It is studied for its combined effect on endogenous growth hormone release and fat metabolism.
A potent three-part research blend pairing two GHRH analogs, Tesamorelin and CJC-1295 (No DAC), with the selective ghrelin agonist Ipamorelin. It is studied for strong synergistic GH release and visceral fat reduction.
A research blend combining the visceral-fat-reducing GHRH analog Tesamorelin with the selective ghrelin agonist Ipamorelin. It is studied for synergistic GH release with a favorable metabolic profile.
Petrelintide is a long-acting amylin analog in phase 2/3 development for weight management, notable for producing meaningful weight loss with markedly less gastrointestinal burden than incretin-based drugs.
Amycretin — now assigned the international nonproprietary name zenagamtide — is a single peptide that agonizes both the GLP-1 and amylin receptors, combining two distinct appetite pathways in one molecule.
MariTide is a once-monthly peptide-antibody conjugate that activates the GLP-1 receptor while blocking the GIP receptor — the opposite GIP strategy from tirzepatide, and the most mechanistically unusual drug in late-stage obesity development.